



UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE
AND PUBLIC HEALTH

Promises and Perils of Proton RT

Altered Fractionation

Søren M. Bentzen, David Westerly, Hidefumi Aoyama


Departments of Human Oncology; Medical Physics; Biostatistics and Medical Informatics,
UW Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA

bentzen@humonc.wisc.edu


Radiation therapy is targeted therapy

- Absolute radioresistance does not exist: treatment failure occurs if and only if...
 - the biologically equivalent dose is not sufficiently high OR ...
 - there is disease outside the high-dose volume
- Normal tissue toxicity arises in irradiated tissues only and shows a dose-volume relationship

The dose-volume trade-off





Fractionation sensitivity – human data




LQ-model: limits of applicability

Low dose hyper-radiosensitivity (?)



Log-linear dose-effect (?)




Dose-distribution ν biological advantage




The "spaghetti" plot



Rib fractures after SBRT



Human tumor fractionation sensitivity



**Dose-fractionation effects
cannot be analyzed without
simultaneous consideration
of dose distribution (and
combined modalities)**



Materials

Virtual clinical trial comparing
6MV IMRT *versus* tomotherapy *versus* proton
therapy

15 patients

5 HCC	60 Gy/10F
5 NSCLC (3 IA, 2 IIIA)	70 Gy/35F
3 prostate	70 Gy/35F
2 skull base	50.4 Gy/28F


PI: Hidefumi Aoyama

Results of liver cases


General trend in DVHs

Tomotherapy reduced the high dose volume in normal liver.


Proton therapy reduced the low dose volume in normal liver.




Hepato-cellular carcinoma




Skull base tumors: EUD for optic chiasm




NSCLC



Symptomatic Pneumonitis vs. Mean Lung Dose



Pneumonitis – Lung bin protocol




Step 4: Is individualized accelerated radiation possible by using selective mediastinal irradiation and dose prescription on the basis of the MLD? (NCT00573040).

Phase II trial.

De Ruyscher et al. ESTRO 27, 2008

Background . Isotoxic irradiation to a target MLD may lead to the best local tumor control rates vs. toxicity



van Baardwijk et al. *Int J Radiat Oncol Biol Phys* 2008 ("in silico")
van Baardwijk et al. *Int J Radiat Oncol Biol Phys* 2008 (Phase I)


Phase II trial: Radiotherapy

- GTV: primary tumor and the initially PET-positive mediastinal lymph nodes (*not anatomical areas*) or to the pathological positive nodes to the following MLD:
MLD=19 Gy when FeV1 and DLCO > 50 %
MLD=15 Gy when FeV1 and/ or DLCO 40-49 %
MLD=10 Gy when FeV1 and/or DLCO < 40 %

Results

- Median radiation dose: 63.1 ± 13.9 Gy (5.4-79.2)
- Median fractions: 34.8 ± 8.5 (3-44)
- Median overall treatment time: 25.5 ± 7.2 days (2-69)
- Median MLD: 13.6 ± 4.5 Gy (2.4-19.9)
- Median spinal cord dose (Dmax): 37.6 ± 17.3 Gy (0.7-58.4)
- Median follow-up: 24.5 ± 5.6 months (13.3-34.4)

Local Tumor Progression per stage




I: 2.3 %

II: 23.2 %


IIIA: 15.5 %

IIIB: 32.4 %

Tomotherapy



Proton - SS



NSCLC: reduced #F (iso-MLD)

Dose limiting toxicity: symptomatic pneumonitis
 $\alpha/\beta = 3.3 \text{ Gy}$

Reduce number of fractions until iso-MLD reached




CAVEATS

- No consideration of
 - proliferation – may not be too important
 - hypoxia – important??
 - other Organs at Risk – surely important
 - motion and margins
- Iso-dose contours and DVH's are not surrogate endpoints – not even after having been passed through a TCP/NTCP model
- Clinical benefit is more than local control



Distant Metastases per stage



I: 44.8 %

II: 77.8 %

IIIA: 58.0 %

IIIB: 60.0 %

Lung Ca Treatment Philosophy Needs a Massive Bailout!

Landis. Ca: Cancer Statistics. 2008; online

Site	1976	1982	1994	2001	2008	Δ (30 yr)
Prostate	67	73	93	99	99	22 %
Breast	75	76	85	88	89	13 %
Colon	50	55	63	64	66	16 %
Lung	12	13	14	15	16	4 %

5-yr Survival

"High-dose" RT





Sequential CRT



Concurrent CRT



Targeted Drugs



Future Solutions?


- Prevention
- Early diagnosis and treatment

Randomizing protons versus photons

- Equipoise

- Collective and Individual equi (human)
- What if $NTCP_{\text{proton}} \ll NTCP_{\text{photon}}$

$NTCP_{\text{photon}} - NTCP_{\text{proton}}$



IMRT “marginal medicine”....?

For instance, men with early stage prostate cancer who choose radiation therapy might have no co-payment for 3-dimensional conformal radiation but might have to cover the marginal cost if they want more expensive intensity-modulated radiation therapy. Value-based co-payments would promote high-value interventions and discourage use of marginal medicine. It would help...



Steepness of DR curve: fixed # fractions

Assuming the validity of the LQ-model, the following relationship holds up at any response level and irrespective of the exact mathematical form of the dose-response model

$$\gamma_N = \gamma_d \cdot \frac{\alpha/\beta + 2 \cdot d_r}{\alpha/\beta + d_r}$$



The required accuracy in RT

- Random errors $\sim \frac{1}{\sqrt{N}}$
- Major mis-administrations $\sim \frac{1}{N}$
- Systematic dosimetric errors $\sim \gamma_N$
- Precision in dose/F prescription $\sim \gamma_N$
- Required accuracy increases with decreasing fraction number



Thanks!

A green neon-style smiley face with a waving hand, positioned below the 'Thanks!' text.

/SMB